RT Journal Article
SR Electronic
T1 Bronchoscopy in critically ill COVID-19 Patients: microbiological profile and factors related to nosocomial respiratory infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.01.20144683
DO 10.1101/2020.07.01.20144683
A1 Serra, Pere
A1 Centeno, Carmen
A1 Garcia-Olivé, Ignasi
A1 Antuori, Adrià
A1 Casadellà, Maria
A1 Tazi, Rachid
A1 Armestar, Fernando
A1 Fernández, Ester
A1 Andreo, Felipe
A1 Rosell, Antoni
YR 2020
UL http://medrxiv.org/content/early/2020/07/03/2020.07.01.20144683.abstract
AB Background Nosocomial co-infections are a cause of morbidity and mortality in Intensive Care Units (ICU).Objectives Our aim was to describe bronchoscopy findings and analyse co-infection through bronchial aspirate (BA) samples in patients with COVID-19 pneumonia requiring ICU admission.Methods We conducted a retrospective observational study, analysing the BA samples collected from intubated patients with COVID-19 to diagnose nosocomial respiratory infection.Results One-hundred and fifty-five consecutive BA samples were collected from 75 patients. Of them, 90 (58%) were positive cultures for different microorganisms, 11 (7.1%) were polymicrobial, and 37 (23.7%) contained resistant microorganisms. There was a statistically significant association between increased days of orotracheal intubation (OTI) and positive BA (18.9 days versus 10.9 days, p<0.01), polymicrobial infection (22.11 versus 13.54, p<0.01) and isolation of resistant microorganisms (18.88 versus 10.94, p<0.01). In 88% of the cases a change in antibiotic treatment was made.Conclusion Nosocomial respiratory infection in intubated COVID-19 patients seems to be higher than in non-epidemic periods. The longer the intubation period, the greater the probability of co-infection, isolation of resistant microorganisms and polymicrobial infection. Microbiological sampling through BA is an essential tool to manage these patients appropriately.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere are no funding supported in the work presentedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research protocol was approved by the hospital's COVID-19 committee (Reference 2342342/20)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is Availability for any revision.